Navigation Links
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
Date:8/7/2008

re-tax charges for changes in the fair value of warrant liability

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP, net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

(1) Stock option expense -- Non-GAAP net loss and diluted net loss per

common share exclude the impact of the stock option expense recorded

in accordance with SFAS No. 123R. Amicus believes that excluding the

impact of expensing stock options better reflects the recurring

economic characteristics of its business.

(2) Other items -- Non-GAAP net loss and diluted net loss per common

share exclude other unusual or non-recurring items that are evaluated

on an individual basis. Amicus' evaluation of whether to exclude an

item for purposes of determining its non-GAAP financial measures

considers both the quantitative and qualitative aspects of the item,

including, among other things (i) its size and nature, (ii) whether

or not it relates to its ongoing business operations, and (iii)

whether or not Amicus expects it to occur as part of its normal

business on a regular basis. Items excluded for purposes of

determining non-GAAP net loss and
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
3. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
9. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
10. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
11. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Headquartered in ... a diversified company comprised of several specialized partners focused ... and the proven expertise of its team of professionals ... WholeHealth Products, line of more than 10 professional diagnostic ... its more than 8 retail consumer tests is proud ...
(Date:9/30/2014)... , Sept. 30, 2014  Synapse Biomedical Inc. ( ... enrollment of the post-approval study of its NeuRx ... needed to meet the FDA enrollment requirement was ... of schedule.  The NeuRx DPS®, which is the ... for ALS patients, is a humanitarian device that ...
(Date:9/30/2014)... 30, 2014 Summary This report ... pharmaceutical companies regarding their Information & Communications Technology ... companies currently allocate their ICT budgets across the ... IT services, communications, and consulting. Key ... companies highlights that X% of respondents anticipate an ...
Breaking Medicine Technology:WholeHealth Products Announces The Discovery Of The "Autism And Fragile X" Microwell And Rapid Diagnostic Test 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 2ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 3
... 7, 2011 Healthmark Industries was honored with two ... Healthcare Central Service Personnel (MSHCSP). At last ... presented with the Lifetime Honorary Achievement Award for his ... The same night Healthmark was also awarded ...
... Among the first healthcare providers to have money in ... health record (EHR) incentive program -- are two Texas ... Canadian, Texas. Both Stamford and Hemphill quickly ... meaningful use to be among the initial 37 hospitals ...
Cached Medicine Technology:Two Texas Hospitals Leverage Prognosis EHR to Meet Meaningful Use Requirements and Receive ARRA Incentive Funds 2
(Date:9/30/2014)... Hospice & Palliative Care of ... gala, honoring three outstanding individuals for their commitment ... provide extraordinary and dignified comfort, care and compassion ... life-limiting illness. , The event was held at ... recognized William (Bill) J. McGuinness, Director of Tiffany ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Dr. Karl ... knee pain program of care that is dramatically ... , His clinic—Johnson Chiropractic Neurology & Nutrition—applies a proprietary, ... knee. It also addresses sources of inflammation, neurology of ... the “neurokinetic chain” from the brain to the spine, ...
(Date:9/30/2014)... WASHINGTON (Sept. 30, 2014) Levothyroxine is considered the ... and a new review of therapies for the condition ... not altered that assessment, say a team of investigators.,1Their ... journal Thyroid , finds insufficient consistent data exist ... whether generic, or sold under various trade names, such ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 Healthcare ... at the National Association of Health Advocacy Consultants (#NAHAC) ... Healthcare Advocacy” (#NAHAC14) to be held October 30th - ... its debut at NAHAC14: Standards and Best Practices for ... grows into a profession, advocates have needed a set ...
(Date:9/30/2014)... September 30, 2014 Market Research ... is a professional and in-depth market survey on ... reviews the basic information of Cialis including its ... explores global and China’s top manufacturers of Cialis ... market share etc. , The report further analyzes ...
Breaking Medicine News(10 mins):Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4
... , TUESDAY, March 1 (HealthDay News) -- A ... hospitals for sepsis -- a potentially life-threatening bacterial infection in ... those treated at other hospitals. Researchers analyzed data from ... sepsis between June 2004 and June 2006. In total, there ...
... over time been able to show that medicine designed ... serious diseases such as cancer. However, now research also ... part in the drug delivery process. "Researchers ... of viruses. The nanoparticles are effective for drug delivery ...
... ATLANTA March 1, 2011 A new report from ... the 141,000 cases and 49,000 deaths from colorectal cancer ... prevented by increasing the use of established screening tests ... The report, Colorectal Cancer Facts & Figures 2011-2013, released ...
... Invasive plant species have long had a reputation as being ... Stan Harpole, assistant professor of ecology, evolution and organismal biology ... of more than 70 researchers working at 65 sites worldwide ... it is true that problematic invasive species often spread widely ...
... Los Angeles, CA (February 28, 2011) Eating more tomatoes ... the risk of conditions such as cancer, osteoporosis and ... American Journal of Lifestyle Medicine , (published by SAGE). ... tomatoes and tomato products than any others. Researchers Britt ...
... , TUESDAY, March 1 (HealthDay News) -- For ... to relieve symptoms and result in major improvements in ... Up to 20 percent of women in their childbearing ... Not all fibroids cause symptoms, but some patients experience ...
Cached Medicine News:Health News:Hospital Spending Doesn't Affect Sepsis Survival Rates 2Health News:Research provides new findings on drug delivery with nanoparticles 2Health News:New report says large proportion of colorectal cancer deaths could be prevented 2Health News:Global ISU study: Invasive species widespread, but not more than at home range 2Health News:Health benefits of eating tomatoes emerge 2Health News:Uterine Fibroid Treatments Seem to Boost Quality of Life 2
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: